(Reuters) -Regeneron Pharmaceuticals said on Tuesday it had entered into a deal valued at more than $3 billion with contract drug developer Fujifilm Diosynth to expand its U.S. manufacturing capacity.
Major U.S. drugmakers, including Eli Lilly and Johnson & Johnson , have announced additional investments in their U.S. production as they grapple with the threat of drug import duties from President Donald Trump’s administration.
Regeneron said the deal would nearly double its U.S. manufacturing capability, adding that an expansion of about $3.6 billion of its Tarrytown, New York-based facility is also underway.
Tokyo-based Fujifilm Diosynth, under the terms of the deal, will manufacture and supply drug products for Regeneron’s biologic medicines for a span of 10 years at its North Carolina-based facility, which is set to be operational later this year.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas)
Comments